Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose- and regimen-ranging study of egg-derived inactivated A/H1N1 monovalent subunit influenza vaccine (with or without MF59) in healthy children and adults
2014-005185-30Phase 3
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of monovalent H1N1 influenza virus vaccine in Influenza A infection and influenza A(H1N1)2009 (H1N1) (2 arms), sponsored by Novartis. Primary endpoint: Seroconversion and HI titer ≥1:40 in children 3 to 17 years.
02
Drugs
monovalent H1N1 influenza virus vaccine
03
Conditions
Influenza A infectioninfluenza A(H1N1)2009 (H1N1)
Beyond the preview
Go deeper on 2014-005185-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005185-30.